Merck & Co., Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
Merck & Co., Inc. (MRK) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $3.31 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-02-24
- Merck & Co., Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2010-03-31 was -$1.06B.
- Merck & Co., Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2009-03-31 was -$1.41B.
- Merck & Co., Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was $3.31B, a 133.55% increase from fiscal 2024.
- Merck & Co., Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was $1.42B, a 38.81% decline from fiscal 2023.
- Merck & Co., Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $2.31B, a 57.09% increase from fiscal 2022.
- Merck & Co., Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was $1.47B, a 16.21% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $3.31B 10-K · filed 2026-02-24 | ||
| 2024-12-31 | $1.42B 10-K · filed 2026-02-24 | ||
| 2023-12-31 | $2.31B 10-K · filed 2026-02-24 | ||
| 2022-12-31 | $1.47B 10-K · filed 2025-02-25 | ||
| 2021-12-31 | $1.76B 10-K · filed 2024-02-26 | ||
| 2020-12-31 | $2.43B 10-K · filed 2023-02-24 | $2.43B 10-K · filed 2021-02-25 | |
| 2019-12-31 | -$70.00M 10-K · filed 2022-02-25 | $32.00M 10-K · filed 2020-02-26 | |
| 2018-12-31 | $674.00M 10-K · filed 2021-02-25 | ||
| 2017-12-31 | $1.09B 10-K · filed 2020-02-26 | $1.09B 10-K · filed 2018-02-27 | |
| 2016-12-31 | -$237.00M 10-K · filed 2019-02-27 | ||
| 2015-12-31 | $5.00M 10-K · filed 2018-02-27 | ||
| 2014-12-31 | $98.00M 10-K · filed 2017-02-28 | ||
| 2013-12-31 | -$563.00M 10-K · filed 2016-02-26 | ||
| 2012-12-31 | $1.20B 10-K · filed 2015-02-27 | ||
| 2011-12-31 | $262.00M 10-K · filed 2014-02-27 | ||
| 2010-12-31 | $160.00M 10-K · filed 2013-02-28 | ||
| 2010-03-31 | -$1.06B 10-Q · filed 2010-05-07 | ||
| 2009-12-31 | -$103.00M 10-K · filed 2012-02-28 | $98.80M 10-K · filed 2010-03-01 | |
| 2009-03-31 | -$1.41B 10-Q · filed 2010-05-07 | ||
| 2008-12-31 | $358.00M 10-K · filed 2011-02-28 | -$358.30M 10-K · filed 2010-03-01 | |
| 2007-12-31 | $105.10M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |